Authors' reply
We are pleased that our original letter' has elicited a response from Diagnostic Products Corporation (DPC) but disappointed that Dr Bodlaender considers us to have made 'potentially misleading statements'. We contend that any confusion experienced by Dr Bodlaender arises from a lack of attention to the detail of our letter and supporting references. We illustrate our contention as follows:
First, the steroid cross-reactant which is present in high concentrations in plasma from neonates, and especially from premature neonates, is 17 a-hydroxypregnenolone sulphate and not, as Dr Bodlaender indicates, 17 a-hydroxyprogesterone sulphate (a most uncommon steroid!).
Secondly, we did not state nor imply that direct assays for 17-hydroxyprogesterone (170HP) are not of value for large scale neonatal screening for congenital adrenal hyperplasia (CAH). Indeed, our experience is quite the opposite as our letter and supporting references make clear. However, if 17-OHP results from direct assays are to be the sole diagnostic index of CAH in neonates then the false positive rate will be unacceptably high and it is for that reason that we recommend that elevated results by the direct method be checked by a method involving solvent extraction. We agree wholeheartedly with Dr Honour2 that distress to parents of neonates must be avoided, a fact that necessitates a minimal false positive rate from any screening programme. As Dr Honour is aware we always confirm the diagnosis of CAH by rapid (3 h) measurement of plasma 170HP, using an extraction assay, and by urinary steroid profiling.
Thirdly, we acknowledged that DPC have introduced an improved direct 170HP assay but as Dr Bodlaender indicates this second generation assay is still not free from the problem that we identified.
Finally, it will come as no surprise to anyone working in the area of neonatal steroids that the reference interval for 170HP in neonates is higher than for prepubertal children or for adults. The process of birth and the first few days of life are stressful and we endorse fully Dr Bodlaender's request for 'reliable neonatal reference ranges with both the direct and extracted assays'. We will be happy to collaborate with DPC to achieve this objective for their product.
A 
More on the PST blood collection tubes
Following the availability of an integral blood drawing plasma-separator tube (PST, VACUTAINER, Becton Dickinson) and subsequent favourable comments by Bailey' we were interested in assessing this for routine usage in our laboratory. The PST provides a means of collecting and separating blood in a closed evacuated glass tube system. The tube contains a semi-solid, silicone polymer material, and is coated with lithium heparin to provide specimen anticoagulation. During centrifugation, the gel material moves upwards to the plasma/cell interface forming a barrier separating plasma from cells, thus aiding plasma decanting directly from the collection tube, eliminating the need for manual pipetting or filtering of plasma as required with normal tubes. Apart from examining the suitability of the PST as a plasma collection tube and its effects on plasma analytes we also examined its usefulness as a plasma storage device. A similar study by Bailey' measured the effect on 16 analytes after overnight storage in the PST tube and we report here more comparative and supplementary data. Fifty-eight subjects were sampled by collecting 10 mL of blood into the standard VACUTAINER tube and 10 mL into a PST VACUTAINER tube.
Both tubes were centrifuged at 1917 RCF for 10 min at ambient temperature with tube stoppers in place. The resultant plasma was then analysed using a SMAC I1 (Technicon Instrument Corp, Tarrytown, NY 10591, USA) for 19 analytes and
